Clinical Trials · NCT00774930
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 115
- Start date
- May 2009
- Locations
- 54 sites, 11 countries
- Primary endpoint
- Percentage of Days With Subcutaneous Octreotide as Rescue Medication